Abstract
In synucleinopathies, the presence of an underlying Alzheimer's disease (AD) pathology can be involved in cognitive decline. Cerebrospinal fluid (CSF) profile consistent with amyloidosis, as well as CSF AD signature are sometimes reported in Parkinson's disease (PD) with dementia. Additionally, decreased CSF Aβ42 levels predict earlier appearance of cognitive decline in PD. However, contradictory results are available for CSF AD biomarkers in PD patients with mild cognitive impairment (PD-MCI). Our aim was to assess potential correlation between CSF AD biomarkers and PD-MCI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
